SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| Klinger Shannon Thyme | Chief Legal Officer | 2026-09-04 | Option exercise | 11797 | — |
| Klinger Shannon Thyme | Chief Legal Officer | 2026-09-04 | Tax withholding | 5704 | $849K |
| Mock James M | Chief Financial Officer | 2026-09-04 | Option exercise | 11797 | — |
| Mock James M | Chief Financial Officer | 2026-09-04 | Tax withholding | 5704 | $849K |
| Hoge Stephen | President | 2026-09-01 | Option exercise | 9283 | — |
| Hoge Stephen | President | 2026-09-01 | Tax withholding | 4489 | $630K |
| Klinger Shannon Thyme | Chief Legal Officer | 2026-09-01 | Option exercise 10b5-1 | 3471 | $107K |
| Klinger Shannon Thyme | Chief Legal Officer | 2026-09-01 | Open-market sell 10b5-1 | 3471 | $486K |
| Klinger Shannon Thyme | Chief Legal Officer | 2026-09-01 | Option exercise 10b5-1 | 2166 | — |
| Klinger Shannon Thyme | Chief Legal Officer | 2026-09-01 | Tax withholding 10b5-1 | 1048 | $147K |
| Mock James M | Chief Financial Officer | 2026-09-01 | Option exercise | 2475 | — |
| Mock James M | Chief Financial Officer | 2026-09-01 | Tax withholding | 1197 | $168K |
| Hoge Stephen | President | 2026-08-28 | Option exercise | 611 | — |
| Hoge Stephen | President | 2026-08-28 | Tax withholding | 296 | $42K |
| Klinger Shannon Thyme | Chief Legal Officer | 2026-08-28 | Option exercise | 329 | — |
| Klinger Shannon Thyme | Chief Legal Officer | 2026-08-28 | Tax withholding | 160 | $23K |
| Mock James M | Chief Financial Officer | 2026-08-28 | Option exercise | 329 | — |
| Mock James M | Chief Financial Officer | 2026-08-28 | Tax withholding | 160 | $23K |
| Hoge Stephen | President | 2026-08-27 | Option exercise | 1437 | — |
| Hoge Stephen | President | 2026-08-27 | Tax withholding | 695 | $104K |
Fiscal period ending 2025-12-31 versus 2024-12-31 — view filing on EDGAR →
A newly disclosed covenant compliance risk on the Ares credit facility — where default could trigger acceleration and asset liquidation — combined with a $1.4B cash decline and fresh workforce restructuring signals material financial stress approaching going-concern territory. Regulatory pressure has broadened sharply across MFN pricing, EU AI Act, FDA/CDC policy shifts, and a new DOJ data-transfer rule, while manufacturing execution risks have escalated from prospective to realized. The single easing item (removal of explicit cash breakeven language) is insufficient to offset pervasive worsening across five or more distinct themes.
10 company-specific · 1 eased/removed · 4 common-mode
New disclosure of covenant compliance risk with Ares-led credit facility. Default could trigger acceleration, asset liquidation, and potential inability to repay—material financial and going-concern risk.
Failure to comply with the covenants in our credit agreement could adversely affect our business A failure to comply with the covenants in our credit agreement with lenders led by Ares Capital…
New disclosure of 2025 regulatory changes at FDA/CDC impacting policies, post-marketing commitments, and costs. Escalates regulatory risk beyond prior year's general uncertainty.
Risks related to commercialization and our products Regulatory and market uncertainty have and may continue to impact our business and the markets for our products. Our ability to successfully…
New disclosure of execution risk on near-term strategy, pipeline commercialization, and cash breakeven goal. Signals post-pandemic commercial challenges and selective R&D approach.
We may experience difficulties executing our near-term strategy and prioritized pipeline. While we expect to launch multiple new products over the next several years, our ability to commercialize our…
Cash and investments declined $1.4B year-over-year, with explicit disclosure of $600M term loan drawdown, signaling liquidity pressure and increased reliance on debt financing.
The investment of our cash, cash equivalents and investments is subject to risks which may cause losses and affect the liquidity of these investments. As of December 31, 2025, we had approximately…
Newly disclosed workforce reductions and restructuring initiatives materially escalate operational risk beyond prior expansion-focused language.
Risks related to our business and operations We may encounter difficulties in managing changes to the size, structure and scope of our company. 63 We have experienced significant growth in our…
Added specific disclosure of PREP Act revocation risk and VICP transition uncertainty for COVID vaccine, materially expanding liability exposure beyond prior indemnity language.
Product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of our products. We are exposed to product liability risk related to the development…
European exclusion extended to end-2026; oncology competitive risk newly emphasized as "particularly high"; market share pressure escalated.
The vaccine market, and pharmaceutical market more generally, is intensely competitive, and we may be unable to compete effectively in the market for existing or new products, treatment methods or…
New disclosure of actual manufacturing cost pressures, exit costs, and take-or-pay commitments from lower-than-expected demand. Shifts from prospective to realized operational challenges.
As we grow as a commercial company and our drug development pipeline matures, the increased demand for clinical and commercial supplies from our facilities and third parties may impact our ability to…
Shift from custom Norwood facility with planned Marlborough expansion to purpose-built Marlborough facility. New disclosure of execution risks on turnaround time and cost reduction, escalating manufacturing complexity.
Our intismeran autogene product candidates are uniquely manufactured for each patient using a novel, complex manufacturing process and we may encounter difficulties in production. We custom design…
Prior year stated debt "may preclude" dividends; this year confirms existing credit agreement "contains restrictions" on dividends—a concrete covenant constraint now disclosed.
We do not expect to pay cash dividends for the foreseeable future. We do not currently intend to declare or pay cash dividends on our capital stock and instead intend to retain any future earnings to…
Removal of explicit cash breakeven risk and cost efficiency execution concerns suggests improved financial position or reduced near-term liquidity pressure.
We may be unsuccessful in executing our cost efficiency and portfolio prioritization efforts. Our broad clinical success and recent commercial challenges have necessitated a more selective and paced…
New executive order on MFN pricing creates material regulatory risk to U.S. product revenues and international pricing strategy, with potential for mandatory rulemaking if voluntary compliance fails.
Federal legislative and regulatory efforts to implement reference pricing or most-favored-nation pricing models and other, similar regulatory actions could impact our product revenues and materially…
Escalated regulatory risk: EU AI Act now explicitly cited with fines/penalties; US state patchwork and FDA guidance added; compliance costs and operational restrictions now material concerns.
Our use of generative AI ("GenAI") and other AI technologies presents certain risks and challenges given the emerging nature of AI technologies. The development and use of GenAI and other AI…
New disclosure of DOJ rule restricting sensitive personal data transfers to countries of concern, with criminal/civil sanctions and operational restrictions on clinical trials.
We are subject to various and evolving laws and regulations governing the privacy and security of personal data, and our failure to comply could result in fines or criminal penalties and damage our…
New disclosure of tariff and trade policy risk. Company acknowledges potential for higher supply costs, margin pressure, and operational disruption, though no current adverse impact reported.
Changes in tariffs and other governmental trade policies could negatively affect our business and results of operations. Recent governmental actions and proposals relating to tariffs and other trade…
Moderna completed a private offering of $3.0 billion aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (including the full exercise of the initial purchasers' option for an additional $400 million) to qualified institutional buyers under Rule 144A and Section 4(a)(2). The notes are general senior unsecured obligations with a conversion rate of 4.7487 shares per $1,000 principal, maturity date of March 1, 2032, and specified redemption and fundamental change repurchase provisions.
View raw filing on EDGAR →Moderna issued a press release on July 31, 2026 announcing its second quarter 2026 financial results, including revenue of $145 million, GAAP net loss of $(0.8) billion, and GAAP EPS of $(1.97). The filing includes condensed consolidated financial statements (income statement, balance sheet, and cash flow statement) and updated 2026 financial guidance. This is a standard quarterly earnings disclosure under Item 2.02.
View raw filing on EDGAR →Michael McDonnell was appointed to Moderna's Board of Directors effective July 8, 2026, and simultaneously appointed to the Audit Committee. McDonnell brings extensive CFO experience from major life sciences companies including Biogen and IQVIA.
View raw filing on EDGAR →